Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Blin

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 17, 2015
Antihypertensive drugs, hypotension, and ischemic colitisPatrick Blin
Handbook of Experimental Pharmacology|November 27, 2019
PharmacoepidemiologyNicholas Moore, Patrick Blin, Cécile Droz
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 26, 2019
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in FranceGérard de Pouvourville, Patrick Blin, Pierre Karam
BMJ (Clinical Research Ed.)|March 14, 2013
Is paracetamol hepatotoxic at normal doses?Nicholas D Moore, Ezgi Gulmez, Patrick Blin
Journal of Hepatology|May 20, 2014
New oral anticoagulants (NOAC) and liver injuryNicholas Moore, Patrick Blin, Sinem-Ezgi Gulmez
Therapie|October 19, 2019
Pharmacovigilance - The next chapterNicholas Moore, Driss Berdaï, Patrick Blin, et al.
Expert Opinion on Drug Safety|November 22, 2013
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTCNicholas Moore, Francesco Salvo, Mai Duong, et al.
Drug Safety|June 13, 2020
Does Ibuprofen Worsen COVID-19?Nicholas Moore, Bruce Carleton, Patrick Blin, et al.
Investigative Ophthalmology & Visual Science|September 28, 2006
Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov modelJean-François Korobelnik, Nicholas Moore, Patrick Blin, et al.
Therapie|November 28, 2018
Pharmacoepidemiology of non-steroidal anti-inflammatory drugsNicholas Moore, Mai Duong, Sinem Ezgi Gulmez, et al.
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 17, 2015
Antihypertensive drugs, hypotension, and ischemic colitisPatrick Blin
Handbook of Experimental Pharmacology|November 27, 2019
PharmacoepidemiologyNicholas Moore, Patrick Blin, Cécile Droz
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 26, 2019
The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in FranceGérard de Pouvourville, Patrick Blin, Pierre Karam
BMJ (Clinical Research Ed.)|March 14, 2013
Is paracetamol hepatotoxic at normal doses?Nicholas D Moore, Ezgi Gulmez, Patrick Blin
Journal of Hepatology|May 20, 2014
New oral anticoagulants (NOAC) and liver injuryNicholas Moore, Patrick Blin, Sinem-Ezgi Gulmez
Therapie|October 19, 2019
Pharmacovigilance - The next chapterNicholas Moore, Driss Berdaï, Patrick Blin, et al.
Expert Opinion on Drug Safety|November 22, 2013
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTCNicholas Moore, Francesco Salvo, Mai Duong, et al.
Drug Safety|June 13, 2020
Does Ibuprofen Worsen COVID-19?Nicholas Moore, Bruce Carleton, Patrick Blin, et al.
Investigative Ophthalmology & Visual Science|September 28, 2006
Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov modelJean-François Korobelnik, Nicholas Moore, Patrick Blin, et al.
Therapie|November 28, 2018
Pharmacoepidemiology of non-steroidal anti-inflammatory drugsNicholas Moore, Mai Duong, Sinem Ezgi Gulmez, et al.
Pageof 10